Results 11 to 20 of about 54,594 (319)

Design and engineering of bispecific antibodies: insights and practical considerations

Frontiers in Bioengineering and Biotechnology
Bispecific antibodies (bsAbs) have attracted significant attention due to their dual binding activity, which permits simultaneous targeting of antigens and synergistic binding effects beyond what can be obtained even with combinations of conventional ...
Andreas V. Madsen, Lasse E. Pedersen, Peter Kristensen, Steffen Goletz   +3 more
doaj   +2 more sources

Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.

New England Journal of Medicine, 2022
BACKGROUND G protein-coupled receptor, family C, group 5, member D (GPRC5D) is an orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody against CD3 and GPRC5D, redirects T cells to mediate killing of GPRC5D-expressing ...
A. Chari, M. Minnema, J. Berdeja, A. Oriol, N. V. D. van de Donk, P. Rodríguez-Otero, E. Askari, M. Mateos, L. Costa, J. Caers, R. Verona, S. Girgis, Shiyi Yang, R. Goldsmith, Xiang Yao, K. Pillarisetti, B. Hilder, Jeffery Russell, J. Goldberg, A. Krishnan   +19 more
semanticscholar   +1 more source

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity

mAbs, 2023
Clinical studies have shown that combination therapy of antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) significantly improves clinical benefit over PD-1 antibody alone. However, broad application of this
X. Pang, Zhao-liang Huang, T. Zhong, Peng Zhang, Z. Wang, Michelle Xia, Baiyong Li   +6 more
semanticscholar   +1 more source

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

Blood Cancer Journal, 2023
Bispecific antibodies (BsAbs) are emerging as an important novel class of immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be more widely used in clinical practice.
N. Raje, K. Anderson, H. Einsele, Y. Efebera, F. Gay, S. Hammond, A. Lesokhin, S. Lonial, H. Ludwig, P. Moreau, K. Patel, K. Ramasamy, M. Mateos   +12 more
semanticscholar   +1 more source

Serum albumin binding knob domains engineered within a VH framework III bispecific antibody format and as chimeric peptides

Frontiers in Immunology, 2023
BackgroundSerum albumin binding is an established mechanism to extend the serum half-life of antibody fragments and peptides. The cysteine rich knob domains, isolated from bovine antibody ultralong CDRH3, are the smallest single chain antibody fragments ...
Ralph Adams, Callum Joyce, Mikhail Kuravskiy, Katriona Harrison, Katriona Harrison, Zainab Ahdash, Matthew Balmforth, Kelda Chia, Cinzia Marceddu, Matthew Coates, James Snowden, Emmanuel Goursaud, Karelle Ménochet, Jean van den Elsen, Richard J. Payne, Richard J. Payne, Alastair D. G. Lawson, Anthony Scott-Tucker, Alex Macpherson   +18 more
doaj   +1 more source

THE ALBUMIN-BINDING DOMAIN AS A SCAFFOLD FOR PROTEIN ENGINEERING

Computational and Structural Biotechnology Journal, 2013
The albumin-binding domain is a small, three-helical protein domain found in various surface proteins expressed by gram-positive bacteria. Albumin binding is important in bacterial pathogenesis and several homologous domains have been identified.
Johan Nilvebrant, Sophia Hober
doaj   +1 more source

Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma

Drugs in Context, 2021
Immunotherapy has revolutionized the treatment of cancers. There are several approaches, including naked monoclonal antibodies, antibody–drug conjugates, immune-checkpoint inhibitors and chimeric antigen receptor T cell therapies with important success ...
Omar Castaneda-Puglianini, Julio C Chavez   +1 more
doaj   +1 more source

The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial

Nature Medicine, 2023
The bispecific molecule tebotelimab, which blocks both PD-1 and LAG-3, is well tolerated as a monotherapy and in combination with the anti-HER-2 antibody margetuximab and elicits encouraging clinical activity in solid tumors with high LAG-3 levels and/or
J. Luke, Manish R Patel, G. Blumenschein, E. Hamilton, B. Chmielowski, S. Ulahannan, R. Connolly, Cesar A. Santa-Maria, Jie Wang, S. Bahadur, A. Weickhardt, A. Asch, G. Mallesara, P. Clingan, M. Długosz-Danecka, M. Tomaszewska-Kiecana, H. Pylypenko, N. Hamad, H. Kindler, B. Sumrow, P. Kaminker, Francine Z Chen, Xiaoyu Zhang, Kalpana Shah, Douglas H. Smith, Anushka De Costa, Jonathan C. Li, Hua Li, Jichao Sun, Paul A. Moore   +29 more
semanticscholar   +1 more source

The Development of Bispecific Hexavalent Antibodies as a Novel Class of DOCK-AND-LOCKTM (DNLTM) Complexes

Antibodies, 2013
The DOCK-AND-LOCKTM (DNLTM) method provides a modular approach to develop multivalent, multifunctional complexes of defined structures, of which bispecific hexavalent antibodies (bsHexAbs) are prominent examples with potential applications in targeted ...
Chien-Hsing Chang, Edmund A. Rossi, Yang Wang, Thomas M. Cardillo, David M. Goldenberg   +4 more
doaj   +1 more source

Bispecific antibodies

Drug Discovery Today, 2015
Bispecific antibodies have emerged as molecules with a multitude of ...
Kontermann, Roland E., Brinkmann, Ulrich
openaire   +3 more sources